These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30596969)

  • 1. Inhibition of heat shock protein 70 blocks the development of cardiac hypertrophy by modulating the phosphorylation of histone deacetylase 2.
    Yoon S; Kim M; Min HK; Lee YU; Kwon DH; Lee M; Lee S; Kook T; Joung H; Nam KI; Ahn Y; Kim YK; Kim J; Park WJ; McMullen JR; Eom GH; Kook H
    Cardiovasc Res; 2019 Nov; 115(13):1850-1860. PubMed ID: 30596969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Casein kinase-2α1 induces hypertrophic response by phosphorylation of histone deacetylase 2 S394 and its activation in the heart.
    Eom GH; Cho YK; Ko JH; Shin S; Choe N; Kim Y; Joung H; Kim HS; Nam KI; Kee HJ; Kook H
    Circulation; 2011 May; 123(21):2392-403. PubMed ID: 21576649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PP2A negatively regulates the hypertrophic response by dephosphorylating HDAC2 S394 in the heart.
    Yoon S; Kook T; Min HK; Kwon DH; Cho YK; Kim M; Shin S; Joung H; Jeong SH; Lee S; Kang G; Park Y; Kim YS; Ahn Y; McMullen JR; Gergs U; Neumann J; Kim KK; Kim J; Nam KI; Kim YK; Kook H; Eom GH
    Exp Mol Med; 2018 Jul; 50(7):1-14. PubMed ID: 30050113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy.
    Kee HJ; Eom GH; Joung H; Shin S; Kim JR; Cho YK; Choe N; Sim BW; Jo D; Jeong MH; Kim KK; Seo JS; Kook H
    Circ Res; 2008 Nov; 103(11):1259-69. PubMed ID: 18849323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of acetylation of histone deacetylase 2 by p300/CBP-associated factor/histone deacetylase 5 in the development of cardiac hypertrophy.
    Eom GH; Nam YS; Oh JG; Choe N; Min HK; Yoo EK; Kang G; Nguyen VH; Min JJ; Kim JK; Lee IK; Bassel-Duby R; Olson EN; Park WJ; Kook H
    Circ Res; 2014 Mar; 114(7):1133-43. PubMed ID: 24526703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quercetin Prevents In Vivo and In Vitro Myocardial Hypertrophy Through the Proteasome-GSK-3 Pathway.
    Chen K; Rekep M; Wei W; Wu Q; Xue Q; Li S; Tian J; Yi Q; Zhang G; Zhang G; Xiao Q; Luo J; Liu Y
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):5-21. PubMed ID: 29435775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Disintegrin and Metalloprotease-22 Attenuates Hypertrophic Remodeling in Mice Through Inhibition of the Protein Kinase B Signaling Pathway.
    Ren L; Wu C; Yang K; Chen S; Ye P; Wu J; Zhang A; Huang X; Wang K; Deng P; Ding X; Chen M; Xia J
    J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29358191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and regulation of type 2A protein phosphatases and alpha4 signalling in cardiac health and hypertrophy.
    Eleftheriadou O; Boguslavskyi A; Longman MR; Cowan J; Francois A; Heads RJ; Wadzinski BE; Ryan A; Shattock MJ; Snabaitis AK
    Basic Res Cardiol; 2017 Jul; 112(4):37. PubMed ID: 28526910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choline ameliorates cardiac hypertrophy by regulating metabolic remodelling and UPRmt through SIRT3-AMPK pathway.
    Xu M; Xue RQ; Lu Y; Yong SY; Wu Q; Cui YL; Zuo XT; Yu XJ; Zhao M; Zang WJ
    Cardiovasc Res; 2019 Mar; 115(3):530-545. PubMed ID: 30165480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NADPH oxidase-4 promotes eccentric cardiac hypertrophy in response to volume overload.
    Schnelle M; Sawyer I; Anilkumar N; Mohamed BA; Richards DA; Toischer K; Zhang M; Catibog N; Sawyer G; Mongue-Din H; Schröder K; Hasenfuss G; Shah AM
    Cardiovasc Res; 2021 Jan; 117(1):178-187. PubMed ID: 31821410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphoinositide 3-kinase p110α is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction.
    Weeks KL; Gao X; Du XJ; Boey EJ; Matsumoto A; Bernardo BC; Kiriazis H; Cemerlang N; Tan JW; Tham YK; Franke TF; Qian H; Bogoyevitch MA; Woodcock EA; Febbraio MA; Gregorevic P; McMullen JR
    Circ Heart Fail; 2012 Jul; 5(4):523-34. PubMed ID: 22705768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stachydrine hydrochloride suppresses phenylephrine-induced pathological cardiac hypertrophy by inhibiting the calcineurin/nuclear factor of activated T-cell signalling pathway.
    Zheng J; Tian J; Wang S; Hu P; Wu Q; Shan X; Zhao P; Zhang C; Guo W; Xu M; Chen H; Lu R
    Eur J Pharmacol; 2020 Sep; 883():173386. PubMed ID: 32712088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Berberine Attenuates Cardiac Hypertrophy Through Inhibition of mTOR Signaling Pathway.
    Chen X; Jiang X; Cheng C; Chen J; Huang S; Xu M; Liu S
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):463-473. PubMed ID: 32394178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Xanthohumol attenuates isoprenaline-induced cardiac hypertrophy and fibrosis through regulating PTEN/AKT/mTOR pathway.
    Sun TL; Li WQ; Tong XL; Liu XY; Zhou WH
    Eur J Pharmacol; 2021 Jan; 891():173690. PubMed ID: 33127362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium Butyrate Controls Cardiac Hypertrophy in Experimental Models of Rats.
    Patel BM
    Cardiovasc Toxicol; 2018 Feb; 18(1):1-8. PubMed ID: 28389765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating GRK2 and NFkappaB in the Pathophysiology of Cardiac Hypertrophy.
    Sorriento D; Santulli G; Franco A; Cipolletta E; Napolitano L; Gambardella J; Gomez-Monterrey I; Campiglia P; Trimarco B; Iaccarino G; Ciccarelli M
    J Cardiovasc Transl Res; 2015 Nov; 8(8):493-502. PubMed ID: 26224342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plantamajoside attenuates isoproterenol-induced cardiac hypertrophy associated with the HDAC2 and AKT/ GSK-3β signaling pathway.
    Shang L; Pin L; Zhu S; Zhong X; Zhang Y; Shun M; Liu Y; Hou M
    Chem Biol Interact; 2019 Jul; 307():21-28. PubMed ID: 31009642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiomyocyte-specific expression of CYP2J2 prevents development of cardiac remodelling induced by angiotensin II.
    He Z; Zhang X; Chen C; Wen Z; Hoopes SL; Zeldin DC; Wang DW
    Cardiovasc Res; 2015 Mar; 105(3):304-17. PubMed ID: 25618409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirtuin 1 activation attenuates cardiac fibrosis in a rodent pressure overload model by modifying Smad2/3 transactivation.
    Bugyei-Twum A; Ford C; Civitarese R; Seegobin J; Advani SL; Desjardins JF; Kabir G; Zhang Y; Mitchell M; Switzer J; Thai K; Shen V; Abadeh A; Singh KK; Billia F; Advani A; Gilbert RE; Connelly KA
    Cardiovasc Res; 2018 Oct; 114(12):1629-1641. PubMed ID: 29800064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATF6 Regulates Cardiac Hypertrophy by Transcriptional Induction of the mTORC1 Activator, Rheb.
    Blackwood EA; Hofmann C; Santo Domingo M; Bilal AS; Sarakki A; Stauffer W; Arrieta A; Thuerauf DJ; Kolkhorst FW; Müller OJ; Jakobi T; Dieterich C; Katus HA; Doroudgar S; Glembotski CC
    Circ Res; 2019 Jan; 124(1):79-93. PubMed ID: 30582446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.